Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the Prescription Drugs topic
No spam. Unsubscribe anytime.
District flags GLP-1 weight-loss drugs and gene therapies as major premium drivers
Summary
Benefits staff told the committee that emerging treatments—costly gene therapies and rising GLP-1 medication use for weight loss—are significant contributors to renewal increases; the EBC pool is discussing whether to remove GLP-1-for-weight-loss coverage from the HMO to save an estimated 3–8%.
Nancy Bellosa explained several industry-wide factors behind rising healthcare costs, including high-cost claimants, specialty medications, state mandates, gene therapies, and GLP-1 medications prescribed for weight loss. "Certain emerging gene therapies are extremely high-cost, one-time treatments that can exceed $1 million per patient," Bellosa said, and she added that "the per-member-per-month cost associated with these medications has more than tripled within a single year."
Bellosa said the EBC Pool Board is discussing whether to exclude GLP-1 medications when prescribed solely for weight loss from the HMO plan, with any pool change potentially taking effect July 1, 2027 and possibly lowering premiums by an estimated 3–8%. Committee members noted any such change would not affect GLP-1 coverage when prescribed for diabetes treatment.
